Overview

A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.

Status:
NOT_YET_RECRUITING
Trial end date:
2031-12-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy and safety of HRS-8080 combined with dalpiciclib versus fulvestrant combined with dalpiciclib in patients with locally advanced/metastatic breast cancer who had developed drug resistance to prior adjuvant endocrine therapy.
Phase:
PHASE3
Details
Lead Sponsor:
Shandong Suncadia Medicine Co., Ltd.